- Home
- PHGE vs APRE Comparison
PHGE vs APRE Comparison
Compare PHGE & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- APRE
- Stock Information
- Founded
- PHGE 2015
- APRE 2006
- Country
- PHGE Israel
- APRE United States
- Employees
- PHGE N/A
- APRE N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PHGE Health Care
- APRE Health Care
- Exchange
- PHGE Nasdaq
- APRE Nasdaq
- Market Cap
- PHGE 13.3M
- APRE 13.9M
- IPO Year
- PHGE N/A
- APRE 2019
- Fundamental
- Price
- PHGE $0.60
- APRE $2.33
- Analyst Decision
- PHGE Strong Buy
- APRE Strong Buy
- Analyst Count
- PHGE 2
- APRE 2
- Target Price
- PHGE $13.50
- APRE $15.50
- AVG Volume (30 Days)
- PHGE 126.6K
- APRE 24.9K
- Earning Date
- PHGE 04-02-2025
- APRE 03-25-2025
- Dividend Yield
- PHGE N/A
- APRE N/A
- EPS Growth
- PHGE N/A
- APRE N/A
- EPS
- PHGE N/A
- APRE N/A
- Revenue
- PHGE N/A
- APRE $1,310,839.00
- Revenue This Year
- PHGE N/A
- APRE $134.21
- Revenue Next Year
- PHGE N/A
- APRE N/A
- P/E Ratio
- PHGE N/A
- APRE N/A
- Revenue Growth
- PHGE N/A
- APRE 130.31
- 52 Week Low
- PHGE $0.48
- APRE $2.15
- 52 Week High
- PHGE $6.30
- APRE $8.10
- Technical
- Relative Strength Index (RSI)
- PHGE 35.68
- APRE 32.67
- Support Level
- PHGE $0.60
- APRE $2.21
- Resistance Level
- PHGE $0.69
- APRE $2.79
- Average True Range (ATR)
- PHGE 0.11
- APRE 0.31
- MACD
- PHGE -0.04
- APRE -0.03
- Stochastic Oscillator
- PHGE 3.10
- APRE 7.97
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.